Resisted deep breathing with myofascial release for post‑mastectomy lymphedema and chest pain

Combined Effect of Resisted Deep Breathing and Myofascial Release on Pain, Respiratory Efficiency, Chest Mobility and Lymph Edema in Postmastectomy

Not applicable Interventional Riphah International University · NCT07576270

This trial will try adding resisted deep breathing to myofascial release for people with post‑mastectomy lymphedema to see if it lowers pain and improves breathing and chest mobility.

Quick facts

PhaseNot applicable
Study typeInterventional
Enrollment48 (estimated)
Ages45 Years to 64 Years
SexFemale
SponsorRiphah International University Academic / other
Drugs / interventionschemotherapy, Radiation
Locations1 site (Lahore, Punjab Province)
Trial IDNCT07576270 on ClinicalTrials.gov

What this trial studies

This randomized controlled trial will enroll 48 participants and is planned to be conducted at Riphah Medical Center in Lahore. Participants will be randomized to two groups: one receiving myofascial release plus baseline transcutaneous electrical nerve stimulation (TENS), and the other receiving myofascial release combined with resisted deep breathing plus the same baseline TENS, delivered twice weekly for 12 weeks. Outcomes include pain (Numeric Pain Rating Scale), chest/limb circumferential measurements for chest mobility and lymphedema, and spirometry for respiratory efficiency, with data analyzed using SPSS. Non‑probability convenience sampling will be used for recruitment.

Who should consider this trial

Good fit: Women at least six months after unilateral mastectomy who finished chemotherapy and radiation at least three months earlier and who have pain with early (stage 1) or no lymphedema and limited shoulder mobility are the intended participants.

Not a fit: Patients with bilateral breast surgery or bilateral lymphadenectomy, shoulder conditions that require surgery, recent musculoskeletal injury in adjacent areas, open upper‑limb wounds, circulatory disorders, or prior shoulder surgery for non‑breast‑cancer reasons are unlikely to benefit or be eligible.

Why it matters

Potential benefit: If successful, the combined therapy could reduce pain, improve respiratory function and chest mobility, and help control early lymphedema.

How similar studies have performed: Smaller studies have shown benefits from myofascial release or breathing exercises for post‑surgical pain and mobility, but combining resisted deep breathing with myofascial release is relatively novel with limited high‑quality evidence.

Eligibility criteria

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Radiation therapy and chemotherapy was finished at least three months
* 6 months after mastectomy for breast cancer being diagnosed without lymphedema or with stage 1 lymphedema
* Complete unilateral Mastectomy
* pain and having one or more of the following symptoms: heaviness, numbness, oppression, stiffness, alterations in the function, or mobility of the limited shoulder range of motion.

Exclusion Criteria:

* Presence of shoulder pathologies for which surgical indications exist
* Musculoskeletal injury in adjacent areas (shoulder or neck etc.)
* bilateral surgery for the treatment of breast cancer
* Bilateral lymphadenectomy
* Open wounds on upper limbs
* Circulatory disorders
* History of shoulder surgery for reasons other than breast cancer.

Where this trial is running

Lahore, Punjab Province

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions Post Mastectomy LymphedemaChestLymphedemaPost mastectomyMyofasical releasePain
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.